Loading...
Loading...
- Announced additional cinical efficacy and safey data for Eteplirsen.
- Used for treatment of Duchenne Muscular Dystrophy.
- Intially rallied to $38.45 in premarket trading.
- Retreated and found support at $35.60 off the open and resumed its rally.
- Just reached $39.24, which is just ahead of it's September 25 high ($39.70).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
